vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and S&T BANCORP INC (STBA). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $102.1M, roughly 2.0× S&T BANCORP INC). S&T BANCORP INC runs the higher net margin — 34.4% vs 12.0%, a 22.3% gap on every dollar of revenue. Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 2.6%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

CORT vs STBA — Head-to-Head

Bigger by revenue
CORT
CORT
2.0× larger
CORT
$202.1M
$102.1M
STBA
Higher net margin
STBA
STBA
22.3% more per $
STBA
34.4%
12.0%
CORT
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
2.6%
STBA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CORT
CORT
STBA
STBA
Revenue
$202.1M
$102.1M
Net Profit
$24.3M
$35.1M
Gross Margin
98.7%
Operating Margin
2.2%
Net Margin
12.0%
34.4%
Revenue YoY
11.1%
Net Profit YoY
-21.0%
5.0%
EPS (diluted)
$0.20
$0.94

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
STBA
STBA
Q1 26
$102.1M
Q4 25
$202.1M
$105.3M
Q3 25
$207.6M
$103.0M
Q2 25
$194.4M
$100.1M
Q1 25
$157.2M
$93.8M
Q4 24
$181.9M
$94.3M
Q3 24
$182.5M
$96.4M
Q2 24
$163.8M
$96.9M
Net Profit
CORT
CORT
STBA
STBA
Q1 26
$35.1M
Q4 25
$24.3M
$34.0M
Q3 25
$19.7M
$35.0M
Q2 25
$35.1M
$31.9M
Q1 25
$20.5M
$33.4M
Q4 24
$30.7M
$33.1M
Q3 24
$47.2M
$32.6M
Q2 24
$35.5M
$34.4M
Gross Margin
CORT
CORT
STBA
STBA
Q1 26
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Operating Margin
CORT
CORT
STBA
STBA
Q1 26
Q4 25
2.2%
40.3%
Q3 25
4.9%
42.6%
Q2 25
13.7%
40.0%
Q1 25
2.2%
44.5%
Q4 24
13.9%
43.8%
Q3 24
25.5%
43.0%
Q2 24
21.7%
44.2%
Net Margin
CORT
CORT
STBA
STBA
Q1 26
34.4%
Q4 25
12.0%
32.3%
Q3 25
9.5%
33.9%
Q2 25
18.1%
31.9%
Q1 25
13.1%
35.6%
Q4 24
16.9%
35.1%
Q3 24
25.9%
33.8%
Q2 24
21.7%
35.5%
EPS (diluted)
CORT
CORT
STBA
STBA
Q1 26
$0.94
Q4 25
$0.20
$0.88
Q3 25
$0.16
$0.91
Q2 25
$0.29
$0.83
Q1 25
$0.17
$0.87
Q4 24
$0.25
$0.86
Q3 24
$0.41
$0.85
Q2 24
$0.32
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
STBA
STBA
Cash + ST InvestmentsLiquidity on hand
$372.2M
Total DebtLower is stronger
$100.8M
Stockholders' EquityBook value
$647.8M
$1.4B
Total Assets
$836.7M
$9.9B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
STBA
STBA
Q1 26
Q4 25
$372.2M
$163.4M
Q3 25
$421.7M
$196.2M
Q2 25
$342.2M
$203.1M
Q1 25
$322.8M
$211.8M
Q4 24
$383.3M
$244.8M
Q3 24
$380.3M
$228.1M
Q2 24
$473.2M
$246.3M
Total Debt
CORT
CORT
STBA
STBA
Q1 26
$100.8M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
CORT
CORT
STBA
STBA
Q1 26
$1.4B
Q4 25
$647.8M
$1.5B
Q3 25
$631.9M
$1.5B
Q2 25
$635.8M
$1.4B
Q1 25
$683.3M
$1.4B
Q4 24
$679.6M
$1.4B
Q3 24
$638.8M
$1.4B
Q2 24
$596.2M
$1.3B
Total Assets
CORT
CORT
STBA
STBA
Q1 26
$9.9B
Q4 25
$836.7M
$9.9B
Q3 25
$823.6M
$9.8B
Q2 25
$801.7M
$9.8B
Q1 25
$846.5M
$9.7B
Q4 24
$840.6M
$9.7B
Q3 24
$784.3M
$9.6B
Q2 24
$714.6M
$9.6B
Debt / Equity
CORT
CORT
STBA
STBA
Q1 26
0.07×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
STBA
STBA
Operating Cash FlowLast quarter
$38.4M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
19.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
STBA
STBA
Q1 26
Q4 25
$38.4M
$133.6M
Q3 25
$54.5M
$40.5M
Q2 25
$43.9M
$28.3M
Q1 25
$5.1M
$28.7M
Q4 24
$59.3M
$173.4M
Q3 24
$73.8M
$27.6M
Q2 24
$41.2M
$44.7M
Free Cash Flow
CORT
CORT
STBA
STBA
Q1 26
Q4 25
$38.4M
$128.8M
Q3 25
$39.9M
Q2 25
$43.9M
$27.1M
Q1 25
$5.0M
$27.0M
Q4 24
$59.2M
$170.4M
Q3 24
$72.2M
$26.9M
Q2 24
$40.8M
$43.9M
FCF Margin
CORT
CORT
STBA
STBA
Q1 26
Q4 25
19.0%
122.4%
Q3 25
38.7%
Q2 25
22.6%
27.1%
Q1 25
3.2%
28.8%
Q4 24
32.5%
180.7%
Q3 24
39.5%
28.0%
Q2 24
24.9%
45.3%
Capex Intensity
CORT
CORT
STBA
STBA
Q1 26
Q4 25
0.0%
4.5%
Q3 25
0.0%
0.6%
Q2 25
0.0%
1.2%
Q1 25
0.1%
1.8%
Q4 24
0.1%
3.1%
Q3 24
0.9%
0.7%
Q2 24
0.3%
0.9%
Cash Conversion
CORT
CORT
STBA
STBA
Q1 26
Q4 25
1.58×
3.93×
Q3 25
2.77×
1.16×
Q2 25
1.25×
0.89×
Q1 25
0.25×
0.86×
Q4 24
1.93×
5.24×
Q3 24
1.56×
0.85×
Q2 24
1.16×
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CORT
CORT

Segment breakdown not available.

STBA
STBA

Net Interest Income$88.4M87%
Noninterest Income$13.6M13%

Related Comparisons